Improved antimycobacterial activity of rifampin using solid lipid nanoparticles by unknown
Aboutaleb et al. International Nano Letters 2012, 2:33
http://www.inl-journal.com/content/2/1/33ORIGINAL ARTICLE Open AccessImproved antimycobacterial activity of rifampin
using solid lipid nanoparticles
Ehsan Aboutaleb1, Massoumeh Noori1, Narges Gandomi1, Fatemeh Atyabi2, Mohammad Reza Fazeli3,
Hossein Jamalifar3 and Rassoul Dinarvand1,2*Abstract
Rifampin (RIF) is one of the front-line drugs in therapy of tuberculosis (TB). The emergence of multidrug-resistant
strains of mycobacteria has greatly contributed to the increased incidence of TB. Nano-based formulation of several
antimicrobials has been shown to improve either antibacterial efficacy or pharmacokinetic behavior. In this study,
RIF-loaded solid lipid nanoparticles (SLNs) were prepared by a modified microemulsion-based method and their
particle size, zeta potential, encapsulation efficiency, morphology, and antibacterial activity against Mycobacterium
fortuitum were evaluated. The resulting SLNs were spherical with diameter of about 100 nm, with low negative zeta
potential, and an encapsulation efficiency of 82%. The formulation also sustained the drug release for 72 h. The
antimycobacterial efficacy was greatly improved against M. fortuitum, and the minimum inhibitory concentration of
drug-loaded SLNs was eight times less than free RIF. Drug-free SLNs and the ingredients showed no antibacterial
effect. It can be concluded that as expected, solid lipid nanoparticles are promising vehicles for enhanced
antimycobacterial effect of rifampin.
Keywords: Solid lipid nanoparticles, Rifampin, Antibacterial activity, Mycobacteria, Mycobacterium fortuitum, MIC,
Drug delivery, TuberculosisBackground
Although tuberculosis (TB) is as old as humanity, it is
still one of the most widespread and fatal diseases [1].
One-third of the world’s total population (more than
two billion) are infected with mycobacterium tubercu-
losis [2]. Although it is more common in under devel-
oped and developing countries, it also remains one of
the major concerns among developed countries as well,
due to growing incidences of AIDS [3]. It is reported
that in 2007, about 1.77 million people have died from
TB, and it is estimated that about 9.27 million new TB
cases occur annually [3]. Complete eradication of the
disease in most cases is not successful due to multidrug-
resistant strains of TB. Also, patients may terminate the
treatment because of side effects, prolongation of ther-
apy, or relief of the symptoms [4].* Correspondence: dinarvand@tums.ac.ir
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in any medium, provided the original work is pThe nanoparticulate drug delivery systems can improve
the quality of antibacterial treatment by decreasing side
effects and reducing the frequency of dosing via prolonga-
tion of drug residence time [5]. Solid lipid nanoparticles
(SLNs) are nano-sized drug delivery vectors which hold
the advantages of lipid emulsions, liposomes, and poly-
meric nanoparticles while avoiding numerous disadvan-
tages of these carriers. SLNs are made from physiological
lipids, so there is a very low concern about their safety and
biocompatibility [6]. Additionally, they can carry both
lipophilic and hydrophilic drugs [7] and possess a solid
matrix to control the release rate of loaded drug [8]. They
can be produced on large scale and sterilized by different
procedures with conventional equipment that are used for
the production of lipid-based infusions [9]. Therefore,
SLNs are considered as suitable drug carriers for intraven-
ous administration [10].
Rifampin (RIF) is one of the first-line drugs in therapy
of TB. It is a bactericidal antibiotic, which binds to
DNA-dependent RNA polymerase and inhibits the initi-
ation of RNA synthesis process. It is a wide spectrum
antibiotic but is used most commonly in the treatmentis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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in mycobacterium species, and this phenomenon has
been received with great concerns about the therapy of
TB in the future [3]. Many multiple drug-resistant
mycobacteria have emerged, and their incidents are con-
stantly increasing [3]. Two mechanisms are considered
to be involved in the natural drug resistance of mycobac-
teria: the mycobacterial cell wall permeability barrier
and the active multidrug efflux pumps [12].
The preparation of several nano-sized formulations of
RIF has been reported before, and most of them were
successful in either increasing the antimycobacterial effi-
cacy of RIF or improving its pharmacokinetics [13-17].
Pandey et al. encapsulated three frontline antituberculo-
sis drugs (rifampin, isoniazid, and pyrazinamide) in poly
(lactic-co-glycolic acid nanoparticles and used it orally
against Mycobacterium tuberculosis infection in mice.
Compared to the solution of the same drugs with same
dosage, the outcome of the study was the improvement
of pharmacokinetics, and the authors concluded that
these polymeric nanoparticles could replace 28 conven-
tional doses with only three doses [18]. This group also
successfully utilized the same oral antituberculosis drugs
incorporated in solid lipid nanoparticles against mice tu-
berculosis, and the formulation was also able to reduce
dosing frequency [19]. However, this study was not able
to discriminate between the effects of three individual
drugs, and only the combination effect was studied. Al-
though better pharmacokinetic profile was contributed
to the better performance of the formulation, no direct
antimicrobial challenge tests were provided to examine
the direct antimicrobial performance on Mycobacteria.
Several studies have revealed the ability of SLNs to
deceive P-glycoprotein (P-gp) pump and reduce efflux
by this molecule [20]. P-gp efflux is one of the mechan-
isms of multidrug-resistance not only at the level of M.
tuberculosis but also at the level of somatic cells [21].
Additionally, Bargoni et al. showed that tobramycin-
loaded SLNs concentrate in lungs and concluded that
this increased concentration might help in treating
pulmonary infections [20].
Cerebral tuberculosis infection is a fatal situation that
requires rapid medical intervention; one of the drugs
used in this case is IV RIF; however, the drug cannot
pass the blood–brain barrier (BBB) completely and the
therapy is troublesome [22]. It has been shown before
that SLNs can pass the BBB efficiently [23]. Thus, RIF-
loaded SLNs can also be useful for brain-targeted drug
delivery in case of cerebral tuberculosis.
TB infection in some cases can spread from lungs to
the lymphatic system. So, drug delivery to macrophages
is of crucial importance in TB therapy. SLNs can aid the
delivery of RIF to the lungs as well as to the lymphatic
system [24]. When the SLNs enter the lungs, alveolarmacrophages phagocyte them and transfer them to the
lymphoid tissues [25].
Several studies have shown that the body distribution
of the drug is highly influenced by the size and surface
characters of the SLNs [26]. The nanoparticles with size
of about 100 nm and coated with PEG or PEG-like sur-
factants (Tween 80, Poloxamer 188, etc.) can escape the
RES system and remain in the blood circulation for a
longer time [27].
The goal of this study was to produce RIF-loaded SLN
formulation suitable for intravenous administration.
Therefore, efforts were made to achieve a formulation
with the ideal size of about 100 nm and below and the
highest encapsulation efficiency. A modified microemul-
sion method was utilized to produce high-concentration
SLN formulation.Methods
Materials
RIF was a gift from Hakim Pharmaceutical Co. (Tehran,
Iran). Cetyl palmitate and Tween 80 were purchased
from Merck KGaA (Darmstadt, Germany). Poloxamer
188 was obtained from Synopharm GmbH (Barsbuttel,
Germany). Lowenstein-Jensen medium was from
Merck, AmiconW Ultra-15 centrifuge tubes were from
Millipore Corporation (MA, USA). M. fortuitum
(ATCC 2701P) was provided by the stock culture of De-
partment of Drug and Food Control, Tehran University
of Medical Sciences (Tehran, Iran). Freshly prepared
reverse osmosis (RO) water was used in all experi-
ments. All other chemicals were either reagent or ana-
lysis grade.Preparation of SLNs
SLNs were prepared by a modified microemulsion-based
technique. Generally, microemulsion methods are based
on dilution of a warm microemulsion of drug agent,
lipid, surfactant, and water in a bulk of cold water and
the resulting formulation usually contains a large extent
of water which is difficult to separate. By adding an extra
ultrasonic treatment, the amount of diluting cold water
could be decreased, while the acceptable particle charac-
teristics were saved.
The lipid (cetyl palmitate) and the emulsifiers (Tween
80/Poloxamer 188) were molten and mixed by means of
magnetic stirring. RIF was added to this mixture and suit-
ably stirred at 80°C to ensure that the drug is totally dis-
persed; then, 25 ml of RO water at the same temperature
was added. This coarse pre-emulsion was treated with
ultrasonic (13 watts/10 min/80°C) using the ultrasonic
probe sonication system (Misonix Inc., NY, USA); the
resulting microemulsion was immediately dispersed in
cold deionized water while stirring (2°C to 3°C).
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determinations
The mean aerodynamic diameter (MAD), and polydisper-
sity index (PDI) were determined with the aid of photon
correlation spectroscopy (Zetasizer Nano ZS, Malvern
Instruments, Worcestershire, UK) at 25°C. Zeta potential
was also determined by the above mentioned device. Be-
fore the measurements, samples were diluted appropriately
with RO water to prevent interparticle scattering which
can interfere the results of measurements. Each sample
was analyzed three times and mean ± SD is reported.
Semicontact (tapping) mode atomic force microscopy
(AFM) (Dualscope/Rasterscope C26, Danish Micro En-
gineering, Copenhagen, Denmark) with rectangular can-
tilever (length 230 μm, width 40 μm, thickness 7 μm),
conical tip (height 15 to 20 μm, angle <20°, curvature ra-
dius <10 nm), and resonance frequency of 150 to 190
kHz was used to investigate the morphology and size of
the nanoparticles. Vacuum-dried samples mounted on a
glass cover slip were used for imaging, and areas of 5 ×
5 μm were scanned with resolution of less than 0.1 nm.
To investigate the stability of the formulations, the
samples of each formulation were filled into glass vials
and stored in either controlled room temperature or in a
refrigerator (4°C). After fixed time intervals (4, 24, 72,
and 148 h), the samples were inspected visually for any
possible cake forming, and size measurements were car-
ried out as mentioned above. Formulations with no cake
forming, and size increase of less than 10% during the
148 h, 72 h, 24 h were regarded as stable.
Drug content and encapsulation efficiency measurement
The encapsulation efficiency was indirectly determined by
measuring the concentration of unloaded drug in the dis-
persion medium. Freshly prepared SLN dispersions (2 ml)
were placed in AmiconW Ultra-15 tubes. Using an ultracen-
trifuge (Sigma 3k30, Sigma Laboratory, Osterode,
Germany) at 6,000g for 15 min, the nanoparticles were
separated from the medium. The filtrate was then diluted
with RO water (if necessary), and the RIF concentration
was measured using visible spectrophotometry (CE7500,
Cecil Instruments, Cambridge, UK) using a calibration
curve of rifampin in deionized water at 336 nm. The encap-
sulation efficiency was calculated using the below equation.
Total amount of drug used for the preparation of
SLNS amount of unloaded drug
 !
=







In vitro drug release
In vitro drug release studies were performed by a dialysis
bag method using a 12,000-dalton molecular weight cut-off membrane to retain the nanoparticles, and phosphate
buffer saline (PBS) (pH 7.4, 37°C) as the release medium.
SLNs dispersion (10 ml) was placed in the dialysis bag
(Sigma Laboratories, Osterode, Germany), and both ends
of the bag were clamped. The bag was soaked in 200 ml
release medium. A thermostatic shaker (Unimax 1010,
Heidolph Instruments GmbH & Co. KG, Schwabach,
Germany) at 37°C and rate of 36 cycles per min was
used to mimic biological condition. At fixed time inter-
vals (0, 0.5, 1, 2, 4, 6, 8, 24, 48, 72, and 120 h), 5 ml por-
tions of the medium were removed, and fresh medium
was added to maintain sink condition. Released drug
concentration was determined by spectrophotometry at
336 nm using a standard curve of RIF in PBS. All the
operations were carried out in triplicate.
DSC investigations
A Mettler DSC 823 (Mettler Toledo International, Inc.,
D-Gießen, Germany) was utilized to investigate the dis-
persion of the drug in the nanoparticles and the degree
of crystallinity of lipid core. Degree of crystallinity was
evaluated using the following formula by Freitas and
Muller [28]:
CI% ¼100 ΔHSLN aqueous dispersion
ΔHbulk  lipid concentrationð Þ
The SLNs were freeze-dried prior to analysis using a
Christ alpha 2–4 LD freeze drier (Martin Christ GmbH,
Osterode, Germany). Precisely weighted freeze-dried
SLNs (approximately 10 mg) and each of the ingredients
were filled separately in 40-μl aluminum pans; using ap-
propriate equipment, the pans were sealed and then
heated in comparison to an empty pan as a reference
from 30°C to 310°C (10 K/min) under dry nitrogen
purge (80 ml/min).
Antibacterial activity study
Well diffusion method was utilized to investigate the anti-
microbial efficacy of the RIF-SLNs. Aqueous solution of
RIF with concentration equal to SLNs and drug-free SLN
(made exactly the same as RIF-SLNs without adding the
drug) were used as control groups. Using M. fortuitum
(ATCC 2701P) as a closely related mycobacterium to M.
tuberculosis, the antibacterial efficacy was investigated.
The bacterial suspension with the turbidity compar-
able to 0.5 McFarland was transferred onto the surface
of Lowenstein-Jensen plate using sterile cotton swab.
RIF-loaded SLNs and aqueous solutions of RIF with con-
centration of 220 μg/ml were prepared, then serial dilu-
tions were made from the stock. Diameter wells (8 mm)
were bored on the medium with a cork borer, and 100
μl aliquots of each diluted sample were introduced into
each well. As control group, 100 μl of drug-free SLNs
Figure 1 AFM image of rifampin-loaded SLN formulation (F8).
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the growth of bacteria around the wells was evaluated,
and the minimum inhibitory concentrations (MICs) of
RIF-SLNs and RIF aqueous solution were determined as
the lowest concentration that could inhibit bacterial
growth around the well.
Results
Size, zeta potential, morphology, and stability results
The size (MAD) and zeta potential of some selected for-
mulations are presented in Table 1. Employing more
than 1.5 g cetyl palmitate in the formulation led to
increased sizes and unstable dispersions. At least 2 g
Tween 80 was necessary to stabilize the formulation, but
increasing its amount had no more effect (data not
shown). Adding Poloxamer 188 to the formulation led
to slight increase of the size, but up to 10% of total
surfactant, the effect was negligible. The addition of
Poloxamer 188 contributed to more stable formulations;
also, zeta potential of Tween 80-based nanoparticles
were slightly negative (−7mV), and by increasing the
percent of Poloxamer 188, the zeta potential became
more negative (−12mV).
Dilution ratios of 1:2 and less showed acceptable qual-
ity, but below this ratio (e.g., 1:1) showed either poor
stability or increased sizes. So, the formulation with 1.5 g
cetyl palmitate, 2 g Tween 80, 0.2 g Poloxamer 188, and
dilution ratio of 1:2 was selected for further investigations.
It is also noteworthy that without the ultrasonic treat-
ment, dilution ratios of down to 1:10 demonstrated poor
characteristics (data not shown).
Stability of almost all dispersions in room temperature
was poor, but in 4°C, the stability was acceptable for
most of the formulations especially those which con-
tained Poloxamer 188 (Table 1). Adding the drug (80 mg
rifampin HCl) to the preparation process increased
the size by 3 to 17 nm, but no other change in stability
or zeta potential of the SLNs was demonstrated; this
result has been reported by other authors as well
[29,30]. Figure 1 shows the AFM topography images ofTable 1 Physicochemical characters of some rifampin-loaded
Cetyl palmitate (g) T80 (g) Poloxamer 188 (g) Dispersion ra
F1 1 2 1:2
F2 1 2 1:1
F3 1 3 1:4
F4 1 4 1:4
F5 1 4 1:8
F6 1.5 2 1:2
F7 1.5 4 0.2 1:2
F8 1.5 2 0.2 1:2
a24 h (*), 72 h (**), 148 h (***).SLNs. It clearly shows the spherical nanoparticles with
almost matching dimensions of PCS data.
Drug content and encapsulation efficiency results
Due to the high solubility of RIF in the lipid core, the
encapsulation efficiency was good enough for all the for-
mulations. For the selected formulation, an encapsula-
tion efficiency of approximately 82% was achieved. Drug
loading also reached up to 5% w/w.
In vitro release study
The cumulative release profile of the selected formula-
tion is shown in Figure 2. Release of RIF from SLNs was
evaluated over a 120-h time period. The profile showed
a biphasic pattern; a burst release of about 13% of the
drug in the first hour is believed to be related to
unloaded drug and the drug molecules that are adsorbedformulations
tio Mean diameter (nm) ± SD PDI Zeta potential Stabilitya
102 ± 4 0.2 −8.34 ± 1 *
311 ± 20 0.33 −7.17 ± 4 -
89 ± 4 0.16 −11 ± 2 **
101 ± 4 0.2 −12.1 ± 1 **
104 ± 3 0.3 −13.7 ± 0.5 **
87.8 ± 3 0.3 −11 ± 0.4 **
99.3 ± 4.0 0.18 −10.3 ± 0.5 ***
108.7 ± 5.5 0.18 −10.7 ± 0.5 ***
Figure 2 In vitro drug release from rifampin-loaded SLN formulation (F8) in PBS (pH, 7.4).
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loaded drug. The release profile reaches the plateau
(about 75% of total drug) in about 72 h.DSC investigation results
Thermograms of freeze-dried RIF-SLN, cetyl palmitate,
Tween 80, and RIF are shown in Figure 3. Cetyl palmi-
tate has a melting point of about 60°C, and it is clearly
noticeable in SLNs and cetyl palmitate bulk thermo-
grams. RIF has characteristic endothermic and exother-
mic peaks from 190°C to 260°C, but the peaks are not
visible in the RIF-SLN thermogram. This indicates that
the drug is not in crystalline form and is molecularly dis-
persed in the nanoparticle matrix. Crystallinity index
was calculated based on the previously mentioned for-
mulae, and it was found that the lipid core of the nano-
particles was 43% crystalline.Antibacterial activity results
Regarding the high encapsulation efficiency (almost
82%), the SLN dispersion, not freeze dried, was used for
antibacterial efficacy test. A great improvement in the
antimycobacterial activity of RIF was shown in this
study. The RIF solution needed at least 22-μg/ml con-
centration to effectively inhibit the growth of the bac-
teria, while the SLN formulation could effectively inhibit
the bacterial growth by the concentration of as low as
2.75 μg/ml. This shows at least an eight-time efficacy
improvement in comparison to RIF solution.Drug-free SLNs were also prepared similar to the
preparation of RIF-SLN formulation except no drug was
used. This formulation had no effect on the bacterial
growth, so the improved antibacterial efficacy is related
to the ability of SLN formulation to deliver the drug effi-
ciently to the bacteria and not to the antibacterial effect
of any other ingredients (lipid or surfactants) in the
formulation.Discussion
Microemulsion-based methods have been utilized in sev-
eral studies to produce SLNs [31-33]. In most of the
microemulsion methods, warm microemulsion is dis-
persed in high amount of cold water (typical ratio 1:50),
so the final formulation is much diluted. The removal
process of excess water from the prepared SLN disper-
sion is a difficult task. In this study, a simple modifica-
tion in the method for the preparation of SLNs helped
to increase this ratio to 1:2, and utilizing ultrasonication
to produce microemulsions could efficiently compensate
the effect of high concentration on stability and size of
the formulation. The resultant formulation was as stable
as the traditional microemulsion formulations, and the
size and zeta potentials were also acceptable.
In vitro studies revealed retarded drug release from
the SLNs. About 13% of drug was released in the first
hour. This effect can be related to the adsorbed drug
molecules on the SLNs surface and the unbound drug.
By the end of 24 h, about 50% of drug was released and
Figure 3 DSC thermograms of selected (a) SLN formulation (F8) and (b) bulk materials.
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(75%). This indicates that this formulation can sustain
the drug release in blood stream and hypothetically is
able to lower dosing frequency.
The final formulation included rifampin HCl (80 mg),
cetyl palmitate (1.5 g), Tween 80 (2 g), and Poloxamer
188 (0.2 g). High lipid solubility of RIF led to high
encapsulation efficiency for all the formulations (about
82%), so there was no need to freeze dry SLNs forantibacterial activity tests; the tests were carried out on
SLN dispersions. Results revealed that loading of RIF in
SLNs improved MIC at least eight times compared to
RIF solution against M. fortuitum. As mentioned above,
two mechanisms are responsible for the drug resistance
of mycobacteria: the mycobacterial cell wall permeability
barrier and the active multidrug efflux pumps. SLN for-
mulation can hypothetically manipulate both of them to
increase the efficacy.
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due to their small size and hydrophobic nature which is
similar to gram negative bacterial cell wall. Also, SLNs can
effectively hinder the effect of P-gp pumps [21]. Moreover,
this formulation possibly will be able to decrease the ad-
ministration frequency due to prolonged drug release.
Conclusion
SLN formulation of rifampin with high encapsulation
efficiency was prepared by a microemulsion-based
method with a satisfactory particle size range and
drug release profile. The formulation consisted of
cetyl palmitate (1.5 g) as the lipid core, Tween 80
(2 g), and Poloxamer 188 (0.2 g) as the surfactant.
RIF-loaded SLNs were eight times more effective
than RIF solution against M. fortuitum. This SLN-
based formulation seems to be a good choice for
antimycobacterial formulations.
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